NCT05975905: A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study). |
|
|
| Active, not recruiting | 2 | 113 | Europe, US, RoW | Dose A KER-012, Dose B KER-012, Dose C KER-012, Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks | Keros Therapeutics, Inc. | Pulmonary Arterial Hypertension | 06/25 | 01/27 | | |
